AGF Investments LLC Purchases 5,434 Shares of Exelixis, Inc. (NASDAQ:EXEL)

AGF Investments LLC increased its position in shares of Exelixis, Inc. (NASDAQ:EXEL) by 20.1% during the 3rd quarter, Holdings Channel reports. The firm owned 32,536 shares of the biotechnology company’s stock after acquiring an additional 5,434 shares during the period. AGF Investments LLC’s holdings in Exelixis were worth $688,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in EXEL. FMR LLC raised its position in shares of Exelixis by 32.6% during the 2nd quarter. FMR LLC now owns 20,101,588 shares of the biotechnology company’s stock valued at $366,251,000 after purchasing an additional 4,943,980 shares during the period. JPMorgan Chase & Co. increased its holdings in Exelixis by 24.4% in the 2nd quarter. JPMorgan Chase & Co. now owns 14,133,144 shares of the biotechnology company’s stock valued at $257,507,000 after acquiring an additional 2,770,928 shares during the last quarter. Allianz Asset Management GmbH increased its holdings in Exelixis by 179.2% in the 3rd quarter. Allianz Asset Management GmbH now owns 1,114,673 shares of the biotechnology company’s stock valued at $23,564,000 after acquiring an additional 715,373 shares during the last quarter. BlackRock Inc. increased its holdings in Exelixis by 2.0% in the 3rd quarter. BlackRock Inc. now owns 31,907,047 shares of the biotechnology company’s stock valued at $674,514,000 after acquiring an additional 612,104 shares during the last quarter. Finally, Vanguard Group Inc. increased its holdings in Exelixis by 1.9% in the 2nd quarter. Vanguard Group Inc. now owns 29,944,880 shares of the biotechnology company’s stock valued at $545,596,000 after acquiring an additional 544,702 shares during the last quarter. Hedge funds and other institutional investors own 82.96% of the company’s stock.

In related news, EVP Patrick J. Haley sold 17,236 shares of Exelixis stock in a transaction dated Wednesday, November 24th. The shares were sold at an average price of $17.25, for a total transaction of $297,321.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Peter Lamb sold 47,500 shares of Exelixis stock in a transaction dated Wednesday, December 15th. The shares were sold at an average price of $17.44, for a total transaction of $828,400.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 137,353 shares of company stock valued at $2,450,124. 3.30% of the stock is owned by corporate insiders.

A number of analysts have issued reports on the stock. Jefferies Financial Group assumed coverage on shares of Exelixis in a report on Wednesday, October 6th. They issued a “buy” rating and a $28.00 price target on the stock. TheStreet downgraded shares of Exelixis from a “b-” rating to a “c” rating in a report on Thursday, November 4th. Royal Bank of Canada reduced their price target on shares of Exelixis from $32.00 to $31.00 and set an “outperform” rating on the stock in a report on Wednesday, November 3rd. Oppenheimer dropped their price objective on shares of Exelixis from $30.00 to $29.00 and set an “outperform” rating for the company in a research note on Tuesday, November 2nd. Finally, Piper Sandler started coverage on shares of Exelixis in a research note on Friday, November 19th. They issued an “overweight” rating and a $34.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and ten have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $32.18.

EXEL stock opened at $18.12 on Friday. Exelixis, Inc. has a 12 month low of $15.50 and a 12 month high of $25.77. The company has a 50-day moving average price of $17.86 and a 200 day moving average price of $18.80. The stock has a market cap of $5.73 billion, a PE ratio of 35.53, a P/E/G ratio of 0.56 and a beta of 0.89.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings results on Tuesday, November 2nd. The biotechnology company reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.19 by ($0.07). Exelixis had a return on equity of 8.27% and a net margin of 13.10%. The firm had revenue of $328.42 million for the quarter, compared to analysts’ expectations of $366.34 million. During the same period in the prior year, the firm posted ($0.10) earnings per share. On average, equities research analysts predict that Exelixis, Inc. will post 0.5 earnings per share for the current fiscal year.

Exelixis Profile

Exelixis, Inc is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of COMETRIQ, CABOMETYX, COTELLIC, and MINNEBRO. The company was founded by Corey S. Goodman and Stelios B.

Recommended Story: How can investors invest in the S&P/TSX Index?

Want to see what other hedge funds are holding EXEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelixis, Inc. (NASDAQ:EXEL).

Institutional Ownership by Quarter for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.